Abstract: A transmission method includes receiving, by a terminal, first signaling sent by the network-side device. The first signaling includes at least one of the following dynamic waveform switch enabling indication information, used for enabling dynamic waveform switch; or waveform indication information, used for indicating a switched waveform.

Abstract: A method for determining a longitudinal position of a combined phantom, a computer readable storage medium, and a CT device. The method includes: scanning the combined phantom to obtain a topogram thereof. The combined phantom is fixed to a table top, protrudes beyond the table top, is axially parallel to the longitudinal direction, and includes a plurality of phantoms, one of which is a slice phantom. The method further includes identifying the plurality of phantoms on the topogram, and using an axial center of the slice phantom as the longitudinal position of the combined phantom. The longitudinal position is determined by using the topogram of the combined phantom, and a phantom position is aligned automatically.

Abstract: An apparatus for determining a time domain window, a terminal, and a readable storage medium. The method for determining a time domain window in embodiments of this application includes: determining, by a terminal, a second time domain window in a first time domain window based on first information. The terminal maintains a first transmission characteristic in the second time domain window for target uplink channel repetitions. The first information includes power control information used for each target uplink channel transmission in the target uplink channel repetitions. The first time domain window is a nominal time domain window configured by a network-side device. The first transmission characteristic is a transmission characteristic with consistent power and continuous phase.

Abstract: A Bluetooth communication system is provided, which comprises a Bluetooth host device and a Bluetooth device set. The connections between the Bluetooth host device and the Bluetooth device set complies with the specification of Bluetooth Low Energy Audio technology. The Bluetooth device set comprises at least a first member device and a second member device. The first member device and the second member device may be configured in a first mode wherein uplink audio signal transmission is allowed, and the connections are carried out by isochronous streaming channels respectively. The first member device transmits captured voice data to the Bluetooth host device, while the second member device does not. When an event is triggered, the first member device can notify the second member device through direct wireless connection, so that the first member device and the second member device can carry out subsequent voice input handover procedures.

Abstract: A Bluetooth audio broadcasting system includes: an audio broadcasting device, a first Bluetooth member device, and a second Bluetooth member device. The audio broadcasting device broadcasts BLE audio packets and transmits a predetermined volume instruction to the first Bluetooth member device and the second Bluetooth member device before broadcasting the BLE audio packets. The first Bluetooth member device parses the BLE audio packets to acquire a predetermined audio data, controls a first audio playback circuit to playback the predetermined audio data, and configures an audio volume of the first audio playback circuit in advance according to the predetermined volume instruction. The second Bluetooth member device parses the BLE audio packets to acquire the predetermined audio data, controls a second audio playback circuit to playback the predetermined audio data, and configures an audio volume of the second audio playback circuit in advance according to the predetermined volume instruction.

Abstract: The present disclosure provides herein conjugates of anti-CLDN18.2 antibodies or antigen-binding fragments thereof with radionuclides, the pharmaceutical composition containing the same and the uses thereof in imaging, patient screening, treatment process monitoring and efficacy evaluation.

Abstract: Provided are anti-MASP-2 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.

Abstract: A Bluetooth communication system is provided, which comprises a Bluetooth host device and a Bluetooth device set. The connections between the Bluetooth host device and the Bluetooth device set complies with the specification of Bluetooth Low Energy Audio technology. The Bluetooth device set comprises at least a first member device and a second member device. The first member device and the second member device may be configured in a first mode and a second mode respectively, and the connections are carried out by isochronous streaming channels. The first member device transmits captured voice data to the Bluetooth main control device, while the second member device does not. When an event is triggered, the first member device can notify the second member device through the Bluetooth host device, so that the first member device and the second member device can carry out subsequent voice input handover procedures.

Abstract: This application discloses an information transmission method and apparatus, a terminal, a network side device, and a readable storage medium. The information transmission method in embodiments of this application includes: receiving, by a terminal, first signaling sent by a network side device, where the first signaling includes at least one of the following: first indication information, indicating the terminal to switch a transmission waveform; and waveform information, used for determining information about a target transmission waveform.

Abstract: A random access processing method and apparatus, a terminal, a network-side device, and a storage medium. The random access processing method includes: A terminal transmits a preamble with repetitions on a plurality of ROs. The terminal starts an RAR window, and monitors RAR information. The RAR window satisfies at least one of the following: The RAR window is at least one symbol following a last symbol of a first RO occupied by the preamble with repetitions. The RAR window is at least one symbol following a last symbol of a last RO occupied by the preamble with repetitions. The RAR window is at least one symbol following a last symbol of each RO occupied by the preamble with repetitions.

Abstract: A method for detecting a human behavior includes: obtaining an image to be detected; obtaining a plurality of key points and a plurality of pieces of position information respectively corresponding to the plurality of key points by key-point recognition on the image to be detected; grouping the plurality of key points based on the plurality of pieces of position information to obtain a plurality of key-point groups, the plurality of key-point groups at least including a part of the plurality of key points; and determining a target human behavior based on key points in the plurality of key-point groups.

Abstract: A method of training a target object detection model includes: extracting a plurality of feature maps of a sample image according to a training parameter, fusing the plurality of feature maps to obtain at least one fused feature map, and obtaining an information of a target object based on the at least one fused feature map, by using the target object detection model; determining a loss of the target object detection model based on the information of the target object and a tag information of the sample image, and adjusting the training parameter according to the loss of the target object detection model. A method of detecting a target object and an apparatus are also provided.

Abstract: A method and an apparatus for determining an uplink transmission time window, a terminal, and a network-side device are disclosed. The method for determining an uplink transmission time window is performed by a terminal and includes: obtaining a first indication; and determining, based on the first indication and a first rule, a first time window in which one or more uplink transmissions satisfy a first transmission characteristic.

Abstract: Provided are proteins comprising a PD-L1-binding moiety linked to a TGF?-binding moiety, IL-1-binding moiety, immunostimulatory polypeptides (e.g., soluble LAG3 or soluble CD4) or CD47-binding moiety, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.

Abstract: Disclosed are systems, devices and methods for imaging and image-based sorting of particles in a flow system, including cells in a flow cytometer. In some aspects, a system includes a particle flow device to flow particles through a channel, an imaging system to obtain image data of a particle during flow through the channel, a processing unit to determine a property associated with the particle and to produce a control command for sorting the particle based on sorting criteria associated with particle properties, and an actuator to direct the particle into one of a plurality of output paths of the particle flow device in real-time.

Abstract: The online detection system for type identification and activity measurement of radiations in gas or liquid is provided, which can capture the light signals generated by different radiations in real time, and convert the light signals into the electrical signals, so as to realize the online type identification and activity measurement of the radiations based on the waveforms and the time information of the electrical signals of the different radiations. In addition, based on the characteristic that different radiations have different penetration capabilities, the inner-outer two-layer activity measurement structure is designed, which can discriminate the radiations with the same waveform. Therefore, the present disclosure simplifies the radiation activity measurement process, thereby greatly improving the efficiency of the radiation activity measurement.

Abstract: An electronic device with a force sensing device is disclosed. The electronic device comprises a user input surface defining an exterior surface of the electronic device, a first capacitive sensing element, and a second capacitive sensing element capacitively coupled to the first capacitive sensing element. The electronic device also comprises a first spacing layer between the first and second capacitive sensing elements, and a second spacing layer between the first and second capacitive sensing elements. The first and second spacing layers have different compositions. The electronic device also comprises sensing circuitry coupled to the first and second capacitive sensing elements configured to determine an amount of applied force on the user input surface. The first spacing layer is configured to collapse if the applied force is below a force threshold, and the second spacing layer is configured to collapse if the applied force is above the force threshold.

Abstract: Anti-CLDN18.2 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the diagnostic uses thereof are provided herein.

Abstract: The present disclosure relates to dosing regimens comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds or pharmaceutical compositions, pharmaceutical formulations, or combinations comprising the same; and methods of using such compounds, combinations, and compositions in the treatment or prevention IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases or disorders or where reduction of IKZF2 or IKZF4 protein levels can ameliorate a disease, for example, the treatment of cancers.

Abstract: The invention provided herein provides dosage and dosage regimens for N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine (Compound (1)), or a pharmaceutically acceptable salt thereof, Compound (1) for the treatment of PRC2-mediated diseases or disorders. In addition, the invention provides using such dosage and dosage regimens in methods for treating PRC2-mediated diseases or disorders.